Cumulative metformin linked to mortality post-prostate cancer

August 8, 2013
Cumulative metformin linked to mortality post-prostate cancer
Among elderly men with diabetes, increased cumulative duration of metformin following a prostate cancer diagnosis correlates with decreased all-cause and prostate cancer-specific mortality, according to a study published online Aug. 5 in the Journal of Clinical Oncology.

(HealthDay)—Among elderly men with diabetes, increased cumulative duration of metformin following a prostate cancer (PC) diagnosis correlates with decreased all-cause and PC-specific mortality, according to a study published online Aug. 5 in the Journal of Clinical Oncology.

David Margel, M.D., Ph.D., from the University of Toronto, and colleagues analyzed data from several Ontario health care administrative databases to identify men (>66 years) with incident diabetes who subsequently developed PC. Within the cohort of 3,837 patients, they examined the impact of duration of antidiabetic medication exposure following diagnosis with PC on all-cause and PC-specific mortality.

The researchers found that the median age at PC diagnosis was 75 years. Over a median of 4.64 years of follow-up, 35 percent of patients died, with 7.6 percent dying from PC. The risk of PC-specific and all-cause mortality was significant decreased, in a dose-dependent manner, for cumulative duration of treatment after PC diagnosis. For PC-specific mortality, the adjusted hazard ratio was 0.76 for each additional six months of metformin use. There was also a significant association with all-cause mortality but it declined over time, from a hazard ratio of 0.76 in the first six months to 0.93 between 24 and 30 months. For other antidiabetic drugs there was no relationship with cumulative use and either outcome.

"Increased cumulative duration of metformin exposure after PC diagnosis was associated with decreases in both all-cause and PC-specific mortality among diabetic men," the authors write.

Explore further: Post-breast cancer, metformin has no effect on mortality

More information: Abstract
Full Text (subscription or payment may be required)
Editorial

Related Stories

Post-breast cancer, metformin has no effect on mortality

July 3, 2013
(HealthDay)—For older women with diabetes and breast cancer, there is no association between metformin use and all-cause or breast cancer-specific mortality, according to a study published online April 30 in Diabetes Care.

Lung cancer risk unaffected by metformin use in diabetes

August 30, 2012
(HealthDay)—Patients with type 2 diabetes who take metformin do not have a reduced risk of lung cancer, in contrast to previous observational studies, according to a study published online Aug. 24 in Diabetes Care.

Rate of nephrectomy at lymph node dissection is declining

April 3, 2013
(HealthDay)—Over the last 30 years, the incidence of nephrectomy at post-chemotherapy (PC) retroperitoneal lymph node dissection (RPLND) has steadily declined, according to research published in the March issue of The Journal ...

Incidence and mortality of PCa after termination of PSA-based screening

March 18, 2013
Men who participate in biennial PSA based screening have a lower risk of being diagnosed as well as dying from prostate cancer up to 9 years after their last PSA test, according to the results of a new study to be presented ...

Statin use at cancer diagnosis linked to lower mortality

November 8, 2012
(HealthDay)—For patients with cancer, statin use prior to diagnosis correlates with reduced all-cause and cancer-related mortality, according to a study published in the Nov. 8 issue of the New England Journal of Medicine.

Popular diabetes drug does not improve survival rates after cancer

May 9, 2013
Despite previous scientific studies that suggest diabetes drug metformin has anti-cancer properties, a new, first-of-its-kind study from Women's College Hospital has found the drug may not actually improve survival rates ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.